Procept BioRobotics Revenue Growth Masks Rising Expenses, Guidance Holds
Event summary
- Procept BioRobotics reported Q1 2026 revenue of $83.1 million, a 20% increase YoY.
- U.S. procedures grew by 30% YoY to approximately 12,200, with handpiece sales normalizing to 95% of procedures.
- Operating expenses increased to $86.6 million, driven by investments in commercial expansion, R&D, and a prostate cancer trial.
- The company’s net loss widened to $31.6 million in Q1 2026, compared to $24.7 million in the prior year period.
- Procept received FDA clearance for its second-generation FirstAssist AI™ software.
The big picture
Procept BioRobotics is navigating a period of accelerated growth in the surgical robotics market, but faces challenges in balancing expansion with profitability. The company's focus on operational excellence and commercial discipline, while showing early signs of impact, needs to translate into sustained cost control to justify its valuation. The FDA clearance of FirstAssist AI represents a strategic opportunity to differentiate its platform, but its success hinges on surgeon adoption and demonstrable clinical benefits.
What we're watching
- Cost Control
- Whether Procept can effectively manage operating expenses, particularly R&D and commercial expansion costs, to improve profitability remains a key risk given the widening net loss.
- International Growth
- The sustainability of international revenue growth, currently at 25%, will depend on Procept’s ability to navigate varying regulatory landscapes and competitive pressures in new markets.
- AI Adoption
- The pace at which surgeons adopt and integrate the new FirstAssist AI software into their workflows will determine the extent of its impact on procedure efficiency and overall revenue generation.
Related topics